Medtronic: Medtronic Evolut TAVR: Exceptional Valve Performance At 5 Years In Low-Risk Aortic Stenosis Patients

(RTTNews) - Medtronic plc (MDT) announced data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five ye